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Citrate anion improves chronic 
dialysis efficacy, reduces systemic 
inflammation and prevents 
Chemerin-mediated microvascular 
injury
sergio Dellepiane1, Davide Medica1, Cesare Guarena1, Tiziana Musso2, Alessandro Domenico  
Quercia3, Gianluca Leonardi1, Marita Marengo4, Massimiliano Migliori5, Vincenzo panichi5, 
Luigi Biancone1, Francesco Pizzarelli6, Giovanni Camussi1 & Vincenzo Cantaluppi3
Systemic inflammation and uremic toxins (UT) determine the increased cardiovascular mortality 
observed in chronic hemodialysis (HD) patients. Among UT, the adipokine Chemerin induces vascular 
dysfunction by targeting both endothelial and vascular smooth muscular cells (EC and VSMC). As Citrate 
anion modulates oxidative metabolism, systemic inflammation and vascular function, we evaluated 
whether citrate-buffered dialysis improves HD efficiency, inflammatory parameters and chemerin-
mediated microvascular injury. 45 patients were treated in sequence with acetate, citrate and, again, 
acetate-buffered dialysis solution (3 months per interval). At study admission and after each treatment 
switch, we evaluated dialysis efficacy and circulating levels of chemerin and different inflammatory 
biomarkers. In vitro, we stimulated EC and VSMC with patients’ plasma and we investigated the role of 
chemerin as UT. Citrate dialysis increased HD efficacy and reduced plasma levels of CRP, fibrinogen, IL6 
and chemerin. In vitro, patients’ plasma induced EC and VSMC dysfunction. These effects were reduced 
by citrate-buffered solutions and paralleled by the decrease of chemerin levels. Consistently, chemerin 
receptor knockdown reduced EC and VSMC dysfunction. In conclusion, Switching from acetate to citrate 
improved dialysis efficacy and inflammatory parameters; in vitro, chemerin-induced EC and VSMC injury 
were decreased by using citrate as dialysis buffer.
Chronic hemodialysis (HD) patients suffer from high cardiovascular morbidity and mortality mainly due to a 
chronic systemic inflammation coupled with an aberrant metabolic state1. Several uremic toxins contribute to 
HD-related premature vascular senescence: among them, adipokines adversely influence both systemic metabo-
lism and the vascular system. Chemerin is a 14-kDa adipokine up-regulated in HD patients and known to target 
both the endothelium and vascular muscle cells; moreover, chemerin has been associated with both micro and 
macro-vascular injury2,3.
Acetic acid is widely used as dialysis solution buffer and after a standard HD session its plasmatic levels are 
several times higher than those observed in physiological conditions4,5. Of note, acetic acid has been associated 
with endothelial dysfunction in several studies: moreover, it represents a privileged substrate for fatty acid syn-
thesis in the liver4. Recently, citric acid has been proposed as alternative dialysis buffer due to its anti-coagulant, 
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anti-inflammatory and anti-oxidant properties: indeed, citrate chelates multivalent cations such as iron and 
copper, restores mitochondrial function, increases glutathione production, reduces complement and neutrophil 
activation6,7. Moreover, since citrate down-regulates the clotting cascade, it also improves dialysis efficiency and 
reduces endothelial injury8.
In this study, a cohort of HD patients was treated in sequence with acetate-, citrate- and then (again) 
acetate-buffered dialysis solutions to test whether citrate could reduce the systemic inflammation and microvas-
cular dysfunction observed in end stage chronic kidney disease.
Results
Study population. Enrolment started on October 30th 2014. Of the 45 enrolled patients, thirty-nine com-
pleted the study (by July 2015); 1 dropout was due to diagnosis of invasive cancer, 4 patients underwent kidney 
transplantation and 1 died during the study. Data from dropout patients were not included in the final analysis. 
No major adverse events were associated with study protocol. Clinical data at enrollment are summarized in 
Table 1; main HD related parameters are summarized in Table 2: no significant variations were observed among 
the different study points (T0: study start, T1 end of the first 3-month acetate period, T2: end of the 3-month 
citrate period, T3 end of the second 3-month acetate period).
Citrate buffer improved dialysis efficiency. Dialysis efficacy increased after treatment with citrate buffer 
and subsequently worsened when acetate-containing solution was used (Fig. 1A–C); for all studied parameters, 
no significant variations were observed between T0 and T1 or T1 and T3. The decrease in pre-dialysis serum cre-
atinine from T1 to T2 was not significant (9,0 ± 2,1vs. 8,5 ± 1,9 mg/dl; p = 0,05), whereas the increase between T2 
and T3 was significant (8,5 ± 1,9 vs. 9,4 ± 2,4; p = 0,003). Pre-HD urea was significantly reduced between T1 and 
T2 (p = 0,04), and almost unchanged between T2 and T3, no changes were observed in post-dialysis urea levels 
(Supplementary Fig. 1). Dialysis efficacy was assessed by urea kinetic model according to Daugirdas’ equation9; 
Patients Main Characteristics
Male/Female 64%/36%
Age (year) 62 + 15
Dialysis vintage (year) 10 + 9
OL-HDF (n) 18% (8)
BIC-HD (n) 82% (37)
Vascular Access
AVF (n) 84% (38)
CVC (n) 16% (7)
Temporary CVC 0 (0%)
Comorbidities
Hypertension 85%
Diabetes 20%
Prev. CAD or Stroke 30%
Nephrophaty
GN 28,7%
DN 19%
ADPKD 20%
Urologic 15,6%
Tubulo-Interstitial 6,7%
Other/Unknown 10%
Table 1. Main clinical and dialysis-related parameters. ADPKD: autosomic dominant polycystic kidney 
disease; AVF: arteriovenous fistula; BIC-HD: bicarbonate dialysis; CAD: coronary artery disease, CVC: central 
venous catheter; DN: diabetic nephropathy; GN: glomerulonephritis, OL-HDF: on line hemodiafiltration. Prev.: 
previous.
Variables
T0 T1 T2 T3
pMean SD Mean SD Mean SD Mean SD
Qd 500 0 500 0 500 0 500 0 1
Qb 316,8 25,9 314,2 22,1 311,0 30,4 307,9 21,9 0,65
HD duration 229,2 19,0 230,7 18,6 233,2 19,3 233,6 18,1 0,87
Infusion (OL-HDF only) 22,1 3,3 18,7 3,2 20,5 3,7 23,7 3,5 0,32
UF/session 2,6 0,31 2,5 0,30 2,7 0,32 2,7 0,32 0,78
Table 2. Main dialysis parameters at the different time-points of the study. HD: hemodialysis (any); Qb: blood 
flow; Qd: dialysis solution flow; OL-HDF: on line hemodiafiltration; SD: standard deviation. UF: ultrafiltration.
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eKt/V significantly increased from T1 to T2 (1,38 ± 0,17 vs.1,45 ± 0,18; p = 0,01). Data were also analyzed accord-
ing to dialysis type (standard bicarbonate HD n = 31 vs. HDF n = 8 – Supplementary Figs 2 and 3).
Citrate dialysis improved parameters of systemic inflammation. Inflammation-related biomark-
ers decreased from T1 to T2 and subsequently worsened at T3; not all variations reached statistical significance 
(Fig. 1D–I and Supplementary Figs 2 and 3). In all analysis, no significant differences were observed between T0 
and T1 or T1 and T3. CRP varied from 7,9 ± 8,5 mg/dl at T1 to 5,9 ± 5,7 at T2 (p = 0,031). Fibrinogen decreased 
from 417 ± 106 mg/dl at T1 to 381 ± 85 at T2 and was 414 ± 92 at T3 (T1 vs. T2 p = 0,01; T2 vs. T3 p = 0,006). 
No significant homocystein variations were observed; surprisingly, ADMA increased from 86 ± 61 ng/ml at T1 
to 99 ± 63 at T2 and then decreased to 69 ± 52 at T3 (T1 vs. T2 p = 0,39; T2 vs. T3 0,01). Finally, the adipokine 
chemerin decreased from T1 to T2, this variation was significant also when patients were analyzed according 
to dialysis type (standard bicarbonate HD vs. HDF – Supplementary Figs 2 and 3). No significant differences 
of calcium-phosphorus, β2-microglobulin, hemoglobin, erythropoietin resistance index (ERI), acid-base status, 
adverse events (i.e. hypotension, hypoglycemia, clotting etc.), dialysis solution sodium and potassium or OL-HDF 
reinfusion volume were observed (data not shown). As Chemerin has been related to patient body weight and 
nutritional status10, we evaluated post-dialysis body weight and normalized protein catabolic rate (nPCR, a vali-
dated index of dialysis patients’ nutrition state) at all study time points (Supplementary Fig. 4). No changes were 
observed in these 2 parameters.
In vitro studies on human endothelial cells (EC) and vascular smooth muscle cells (VSMC). Uremic 
milieu is known to cause microvascular dysfunction trough several mechanisms including a direct cytotoxic effect 
of uremic toxins on EC and VSMC11,12. Hence, we investigated in vitro whether the shift from acetate to citrate 
buffer may improve cell function: to test this hypothesis, we performed functional assays on EC and VSMC using 
patients’ plasma collected at different time points.
In presence of T2 plasma EC angiogenesis on Matrigel was improved (Fig. 2A,B) and a decreased adhesion of 
fluorescent peripheral blood mononuclear cells (PBMC) on EC was observed (Fig. 2C). Consistently, EC apop-
totic rate was significantly decreased after culture with T2 plasma, when compared with plasma from T0, T1 and 
T3 (Fig. 2D).
Figure 1. Patients’ clinical data at the different study time points. (A) Pre-dialysis blood urea nitrogen levels, 
(B) pre-dialysis serum creatinine values, (C) dialysis efficacy estimated with the eKt/V Daugirdas formula (D), 
pre-dialysis values of plasma C-Reactive Protein (CRP), (E) pre-dialysis plasma fibrinogen, (F) pre-dialysis 
serum IL6, (G) pre-dialysis serum ADMA values, (H) pre-dialysis serum homocystein values and (I) pre-
dialysis serum Chemerin measured at the different study time-points. T0: study start; T1: end of 1st acetate 
period (3 months from study start); T2 end of citrate (6 months); T3 end of 2nd acetate period (9 months). 
*p < 0.05 when data were compared with T1; ♯p < 0.05 when data were compared with T2.
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Figure 2. Effect of Citrate buffered-dialysis on human endothelial cells (EC). In all the experiments EC were 
incubated with patients’ plasma collected at different study time points. (A) Representative micrographs of EC 
angiogenesis on matrigel. (B) Quantification of the capillary-like structures generated by EC on matrigel-coated 
plates. (C) Number of adherent Peripheral Blood Mononuclear Cells (PBMC) on a layer of confluent EC. (D) % 
of EC apoptosis (TUNEL test). (E) Representative immunofluorescence micrographs of DAF2DA probe staining 
in EC. (F) Representative immunofluorescence micrographs of ROS probe staining in EC. (G) Flow cytometry 
(FACS) quantification of Nitric Oxygen (NO) bioavailability by DAF2A probe staining. (H) Flow cytometry 
(FACS) Quantification of Reactive Oxygen Species (ROS) generation in EC by appropriate fluorescent probe. T0: 
serum from study start; T1: end of 1st acetate period (3 months from study start); T2 end of citrate treatment (6 
months); T3 end of 2nd acetate period (9 months). *p < 0.05 when data were compared with T1; ♯p < 0.05 when 
data were compared with T2. Scale bar length is 50 μm in all micrographs.
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To test whether the decrease in EC apoptosis and angiogenesis in vitro were associated with an improved cell 
function, we investigated endothelial NO and ROS production by using dedicated fluorescent assays (Fig. 2E–H). 
Compared to T0-1 or T3, NO production was improved by the use of T2 plasma. Of interest, the increase in NO 
activity was not related to ROS over-production; conversely, ROS were down regulated in cells stimulated with 
T2 plasma.
Alizarin red staining was used to detect intracellular calcification of VSMC (Fig. 3); intracellular calcium 
deposits were significantly reduced when cells were stimulated with plasma collected after the citrate dialysis 
period (T2), and this beneficial effect persisted after citrate discontinuation. In order to confirm these results, we 
evaluated by immunofluorescence, qRT-PCR and FACS the expression of RUNX2, a transcription factor strongly 
associated with VSMC calcification13. We found that RUNX2 expression was reduced after stimulation with T2 
plasma in respect to T0, T1 or T3 plasma.
Inhibition of chemerin signaling by specific small interfering RNA (siRNA) in EC and VSMC. 
According to our data, citrate dialysis improved a number of inflammatory parameters potentially affecting vas-
cular function. To specifically evaluate the role of chemerin as mediator of vascular injury, we engineered EC 
and VSMC with an appropriate siRNA to knockdown the chemerin receptor ChemR23 (Supplementary Fig. 5). 
Knockdown and control cells were stimulated with T0 samples from the 5 patients with the highest chemerin 
plasma levels (Fig. 4). After ChemR23-knockdown, EC displayed reduced apoptosis and ROS production, 
increased NO release and angiogenesis when compared to cells transfected with irrelevant-siRNA or wild type 
Figure 3. Effect of Citrate buffered-dialysis on human vascular smooth muscle cell (VSMC). In all the 
experiments VSMC were incubated with patients’ plasma collected at different study time points. (A) 
Representative micrographs of red alizarin staining of VSMC. (B) Representative immunofluorescence 
micrographs of RUNX2 staining of VSMC. (C) Spectrophotometry quantification of red alizarin internalization 
by VSMC. (D) RUNX-2 mRNA relative quantification by qRT-PCR (quantitative Reverse Transcription 
Polymerase Chain Reaction) in VSMC. (E) Flow cytometry (FACS) quantification of RUNX-2 positive VSMC. 
T0: serum from study start; T1: end of 1st acetate period (3 months from study start); T2 end of citrate treatment 
(6 months); T3 end of 2nd acetate period (9 months); O.D.; optical density. *p < 0.05 when data were compared 
with T1; ♯p < 0.05 when data were compared with T2. Scale bar length is 50 μm in all micrographs.
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cells. Additionally, VSMC transfected with ChemR23-siRNA showed decreased alizarin-red staining and reduced 
RUNX2 mRNA expression.
Discussion
In this study, the use of citrate buffer was associated with enhanced dialysis efficacy and a reduction of systemic 
inflammation parameters in a cohort of 45 hemodialysis patients followed for 9 months. We observed a reduc-
tion of pre-dialysis creatinine and urea levels, an improvement of eKt/V and a decrease in several inflammation 
biomarkers such as CRP, fibrinogen, IL6 and the adipokine chemerin. To validate our clinical findings and the 
Figure 4. Effect of Chemerin knockdown on human endothelial and Vascular Smooth Muscle Cell (EC and 
VSMC). Human EC and VSMC were stimulated with the plasma from patients showing the highest chemerin 
levels at study start (n = 5). The following experiments were performed in non-engineered wild type cells (WT), 
after silencing of Chemerin receptor (siRNA ChemR23) or with an irrelevant control siRNA (siRNA CTRL). 
(A) Quantification of apoptotic EC number (TUNEL assay). (B) Quantification of capillary-like structures 
(angiogenesis assay) generated by EC on Matrigel-coated plates. (C) Flow cytometry (FACS) Quantification of 
Nitric Oxygen (NO) bioavailability by DAF2A probe staining in EC. (D) Flow cytometry (FACS) Quantification 
of Reactive Oxygen Species (ROS) generation in EC by appropriate fluorescent probe. (E) Spectrophotometry 
quantification of red alizarin internalization by VSMC. (F) RUNX2 mRNA expression by qRT-PCR (quantitative 
Reverse Transcription Polymerase Chain Reaction). *p < 0.05 siRNA ChemR23 vs. wild type or siRNA control.
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potential role of chemerin in microvascular dysfunction, we investigated in vitro the effects of patients’ plasma 
on cultured EC and VSMC. For both cell types, the cytotoxicity induced by uremic plasma was partially reverted 
when citrate-dialysis serum was tested. Finally, we observed that chemerin is a key mediator of vascular cell 
injury: indeed, the knockdown of its specific receptor ChemR23 on EC and VSMC surface associated with an 
improved cell function.
Despite several technical advances in the extracorporeal techniques, the high mortality rate associated with 
HD is still far to be controlled. Several studies demonstrated that young and non-comorbid HD patients have 
a cardiovascular senescence comparable to elderly subjects without renal failure14–16; on the other hand, the 
association of dialysis need and other major comorbidities exposes patients to an extremely high cardiovascular 
risk1,17,18. For instance, diabetic patients with end stage renal disease have a 2-year mortality close to 50%19,20. 
Fluid overload and electrolyte disorders are major determinants of cardiovascular risk but do not explain the 
whole mortality excess observed in HD patients. Uremic toxin accumulation is responsible for direct cytotoxicity 
on large vessels and microvascular networks11,12,14. Indeed, smooth muscle calcification and chronic endothelial 
dysfunction are two main causes of microvascular injury and are sustained by several molecules overexpressed 
in the uremic milieu.
Citrate anion is the cornerstone of eukaryotic oxidative metabolism trough the citric acid cycle: moreover, it 
chelates and shuttles several polyvalent cations, (i.e. calcium, zinc, silver, copper etc.) and contributes to acid-base 
balance6. Citrate is also a key regulator of mineral bone metabolism as it stabilizes hydroxyapatite crystals and 
reduces bone reabsorption21. In common clinical practice, citrate is effective in treatment of CKD-related met-
abolic acidosis, reduces urinary tract inflammation and inhibits calcium phosphate, calcium oxalate and uric 
acid nephrolithiasis. In the last decade, the use of citrate in extracorporeal renal replacement therapy for Acute 
Kidney Injury (AKI) lead to an authentic revolution: citrate-based local anticoagulation is more effective than 
other strategies (i.e. heparin and direct thrombin inhibitors) and is almost free from systemic adverse effects22. 
Additionally, some authors found that regional citrate anticoagulation down-regulates complement activation, 
neutrophil degranulation and IL1-β secretion23,24. Subsequently, citrate has been proposed as dialysis solution 
buffer in chronic HD; indeed, preliminary studies demonstrated an intra-dialytic hemodynamic improvement 
and a reduced use of heparin6,7.
The impact of citrate on dialysis efficacy is controversial; in a recent study on 44 patients treated with on-line 
hemodiafiltration (ol-HDF) citrate-buffer did not improve treatment efficacy25. However, other authors have 
reached different conclusions: Kossmann et al.26 found a significant increase in Kt/V in 142 patients treated with 
citrate-buffered hemodialysis (non HDF) for 6 months. In accordance with Kossmann’s study and with the results 
of the present study, other groups have found an increased dialyzer half-life27 and a stable dialyzer clearance 
despite a 30% heparin reduction28 in patients treated with citrate-buffered dialysis. Our study enrolled 45 patients, 
of which only 8 were treated with ol-HDF; interestingly, we could not observe the improvement of eKt/V in this 
sub-group. Thus, one could speculate that, due to the higher clearances observed in ol-HDF treatments, a large 
number of patients is required to highlight a possible citrate effect.
The observed increase in dialysis efficacy may be partially explained by the anticlotting proprieties of citrate. 
A reduction in circuit clotting was not detected, probably as a consequence of the few episodes observed (n = 4); 
however, it is reasonable to hypothesize that the down-regulation of the coagulation cascade contributed to main-
tain the efficiency of the dialyzer. Moreover, reduced fibrinogen levels may decrease also blood viscosity and the 
formation of the so-called “protein cake” (the layer of proteins that progressively coats the dialyzer membrane, 
thus affecting treatment efficiency)29.
Adipokines are a family of soluble proteins produced by fat tissue that act as endocrine and paracrine factors. 
These proteins regulate lipid metabolism, the sense of hunger and satiety and many endocrine processes including 
insulin secretion. Dysregulation of adipokine signaling has been recently associated with obesity, diabetes, dys-
lipidemia and chronic inflammation30,31. In the last years, an increasing body of evidence pointed out the role of 
adipokines as uremic toxins and inflammatory mediators; among adipokines, chemerin has been related to CKD 
progression and leucocyte recruitment in renal tissues32,33. In recent studies, chemerin was also found to posi-
tively correlate with systemic inflammation biomakers (i.e. CRP, WBC count), insulin resistance, dyslipidemia 
and hepatic disorders in incident and maintenance HD patients34,35.
In this study, citrate dialysis reduced circulating chemerin levels together with IL6, CRP and fibrinogen. As cit-
rate improves mitochondrial function and oxidative metabolism36, one could speculate that it may directly inhibit 
chemerin expression or signaling. Of interest, the improved chemerin levels persisted after the suspension of 
citrate-buffered dialysis and some of the beneficial effects observed in vitro by using T2 plasma were maintained 
also by using T3 plasma samples.
Nitric Oxide (NO) is known to improve endothelial tropism and function by activating adenylate-ciclase 
intracellular pathway; however, in oxidant conditions, NO release may increase Reactive Oxygen Species (ROS), 
thus triggering tissue injury. In our in vitro experiments, citrate HD (T2) plasma improved the activity of the 
NO-synthase in EC, but this effect was associated to a reduced ROS production. Moreover, T2-plasma stimulated 
EC were less prone to leucocyte recruitment as a probable consequence of the weaker expression of surface adhe-
sion molecules.
Smooth muscle calcification is another pathognomonic feature of uremic vascular dysfunction and leads to 
tunica media mineralization, a lesion known as Monckeberg arterial sclerosis. Our data confirmed that uremic 
plasma induces myocyte trans-differentiation and intracellular calcification by promoting the osteoblastic tran-
scription factor RUNX213,37. Also in this case, citrate use was associated with a reduced cell dysfunction charac-
terized by decreased calcium deposits (stained by alizarin red) and down-regulation of RUNX2 mRNA.
To further investigate whether chemerin is a possible mediator of the observed cytotoxic effects, we selected 
the 5 patients with the highest circulating levels of this adipokine (all at T0) and we repeated the same in vitro 
assays after chemerin-receptor (ChemR23) knockdown by specific siRNA. Our data demonstrated that chemerin 
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inhibition exerted a protective effect (on both EC and VSMC) similar to what observed in presence of plasma 
from citrate HD. Interestingly, our data are consistent with a previous investigation reporting an enhanced pro-
duction of ROS in endothelial cells stimulated by chemerin; consistently with our results, this finding was corre-
lated with an impaired eNOS activity2.
Our data suggest that citrate-buffered solutions may modulate several clinical and biochemical parameters of 
HD patients: however, the present study presents some limits. For a number of studied parameters we found a sig-
nificant improvement from T1 to T2 but not a corresponding worsening after citrate discontinuation (T2 vs. T3), 
this might be related to persisting beneficial effects of citrate treatment but further studies are needed to untangle 
these findings. As this study is mono-centric, larger investigations are needed to confirm our results. Moreover, 
our patients had a relatively low prevalence of diabetes when compared to large HD registry studies38,39, thus our 
data might be not fully applicable to other patients cohorts. Finally, our therapeutic intervention had two com-
ponents (i.e.: acetate removal and citrate use) and we cannot discern their relative contribution to the observed 
improvements.
In conclusion, the switch from acetate to citrate buffer increased dialysis efficacy and simultaneously decreased 
chronic inflammation parameters. Our in vitro data demonstrated that citrate-dialysis prevents EC dysfunction 
and VSMC osteoblastic differentiation, identifying the adipokine chemerin as a possible target to inhibit micro-
vascular injury.
patients and Methods
Inclusion and exclusion criteria. In this monocentric study we enrolled 45 patients from Città della Salute 
e della Scienza University Hospital, Torino, Italy. Inclusion criteria were: age >18 years, creatinine clearance 
<5 ml/min, treatment with bicarbonate HD (BIC-HD) or on-line hemodiafiltration (OL-HDF) 3 times per week 
for at least 6 months. Patients with neoplastic, acute or chronic inflammatory diseases (including active HIV, 
HCV or HBV infection) were excluded. A written informed consent was obtained and the study was conducted in 
accordance with the declaration of Helsinki. Study protocol was reviewed and approved by local ethic committee 
(Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino - A.O. Ordine Mauriziano - 
A.S.L. Città di Torino; study registration number nr. 2CEI 753 – 0064476, June 2013). The trial was also registered 
on www.clinicaltrial.gov (ID: NCT03577249, registration date: June 13, 2018).
Treatment protocol and collected parameters. Total study duration was 9 months; in the first 3 months 
patients were treated with a standard dialysis solution containing 3 mmol/l acetate (Select Bag, Baxter Gambro 
Renal, New Providence NJ), the following 3 months we used an acetate-free solution containing 1 mmol/L cit-
rate (Select Bag Citrate) and the last 3 months again the acetate solution. Except for citrate/acetate content the 
2 solutions were identical; sodium and potassium concentration varied according to patient needs. Each patient 
maintained the same dialysis modality for all the study length (BIC-HD or OL-HDF). We collected patients’ 
plasma at study start (T0) and at the end of the 3 treatment intervals (T1, 2 and 3). Samples were used to perform 
in vitro experiments and to measure inflammatory markers (CRP, fibrinogen, IL6, homocystein, chemerin, and 
asymmetric di-methyl-arginine – ADMA), markers of dialysis efficiency (creatinine, urea, β2-microglobulin) 
and other parameters related to end stage kidney disease (calcium, phosphorus, parathyroid hormone, acid-base 
status, hemoglobin). Basing on recorded variables, we estimated erythropoietin resistance index (ERI) and dialy-
sis efficacy (eKt/V using Daugirdas formula). During each dialysis session, patients were monitored according to 
the best clinical practice of the center17, intradialytic adverse events (i.e. hypotension, hypertension peak, dialysis 
lines clotting, arrhythmias) were recorded. To account for systemic recirculation, post-dialysis blood sampling 
was obtained from the line after have paused dialysis for 5 minutes. Patients were screened for vascular access 
recirculation by glucose infusion test40 when clinically indicated or routinely at least once a month.
Study sample estimation and statistical analysis. The main outcome variable considered for sample 
size estimation was CRP. Assuming that citrate buffered dialysis would have reduced CRP by 30% over 3 months, 
we calculated that the inclusion of 34 patients would have conferred an 80% power to demonstrate a statistically 
significant reduction (α = 0.05, one-tailed test) of this parameter. To account for a 30% drop-out rate, we included 
in the study a total of 45 subjects.
Data analysis was performed by Prism (GraphPad, La Jolla, CA). All data were subjected to D’Agostino- 
Pearsons test to assess variables distribution; continuous non-normal distributed variables were analyzed with 
Mann-Whitney test; normal distributed variables were analyzed with two-tails paired t-test or one way ANOVA 
and Bonferroni multi-comparison test. A p value <0.05 was considered statistically significant. In all figures, 
clinical data are depicted as mean ± standard deviation (SD) or median ± interquartile range (IQR) where appro-
priate, in vitro data are depicted as mean ± standard error mean (SEM).
In vitro studies. In vitro methods are described in details in Supplementary Information.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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